These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16128677)

  • 21. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL; Wang H; Niu J; Chim AM; Sung JJ
    Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A study on efficacy of lamivudine therapy in decompensated cirrhosis of liver due to chronic hepatitis B virus infection.
    Sharma YR; Miah AR; Saha SK; Mohammed S; Rahman M; Roy PK; Hasan M
    Nepal Med Coll J; 2004 Dec; 6(2):106-11. PubMed ID: 16295739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early virological response predicts outcome during extended lamivudine retreatment in patients with chronic hepatitis B who relapsed after initial HBeAg responses.
    Jang JW; Bae SH; Choi JY; Kim CW; Han NI; Han JY; Choi SW; Yoon SK; Chung KW; Sun HS
    J Gastroenterol Hepatol; 2006 Feb; 21(2):384-91. PubMed ID: 16509863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B.
    Chan HL; Wong VW; Hui AY; Tsang SW; Chan JL; Chan HY; Wong GL; Sung JJ
    Antivir Ther; 2006; 11(4):465-71. PubMed ID: 16856620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B.
    Honkoop P; de Man RA; Scholte HR; Zondervan PE; Van Den Berg JW; Rademakers LH; Schalm SW
    Hepatology; 1997 Jul; 26(1):211-5. PubMed ID: 9214472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early mortality in Taiwanese lamivudine-treated patients with chronic hepatitis B-related decompensation: evaluation of the model for end-stage liver disease and index scoring systems as prognostic predictors.
    Dai CY; Chuang WL; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Huang JF; Hsieh MY; Wang LY; Tsai JF; Wen-Yu ; Yu ML
    Clin Ther; 2006 Dec; 28(12):2081-92. PubMed ID: 17296464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.
    Kennedy PT; Phillips N; Chandrasekhar J; Jacobs R; Jacobs M; Dusheiko G
    Liver Int; 2008 May; 28(5):699-704. PubMed ID: 18433396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy.
    Lai MW; Huang SF; Hsu CW; Chang MH; Liaw YF; Yeh CT
    Antivir Ther; 2009; 14(2):249-61. PubMed ID: 19430100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B.
    Shin WG; Park SH; Jang MK; Hahn TH; Kim JB; Lee MS; Kim DJ; Jun SY; Park CK
    Dig Liver Dis; 2008 Apr; 40(4):267-74. PubMed ID: 18055281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
    J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
    Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
    Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.
    Hsu CW; Yeh CT; Chang ML; Liaw YF
    Gastroenterology; 2007 Feb; 132(2):543-50. PubMed ID: 17258721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predictive factors of hepatitis B virus DNA negative conversion among patients with chronic hepatitis B during lamivudine therapy].
    Chen JL; Wang L; Yan J; Zhang L; Yu H; Fan XL
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):273-5. PubMed ID: 17971944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum hyaluronan and laminin level in children with chronic hepatitis B during long-term lamivudine treatment.
    Lebensztejn DM; Skiba E; Sobaniec-Lotowska ME; Kaczmarski M
    Hepatogastroenterology; 2007; 54(75):834-8. PubMed ID: 17591074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.